Journal Title
2022; X(X): XX-XX
doi: 10.11648/j.XXXX.2022XXXX.XX
ISSN: XXXX - XXXX (Print); ISSN: XXXX - XXXX (Online)
Paper Title
Author’s Full Name1, *, Author’s Full Name1, 2
1
Department/Faculty, University, City, Country
2
Department, Institute/Organization, City, Country
Email address:
email1@authorname.com (author name1), email2@authorname.com (author name2)
*
Corresponding author
To cite this article:
Author’s Name. Paper Title. International Journal of XXXXXX. Vol. x, No. x, 2022, pp. x-x. doi: 10.11648/j.xxx.xxxxxxxx.xx.
Received: MM DD, 2022; Accepted: MM DD, 2022; Published: MM DD, 2022
Abstract: An abstract is a short summary of your research paper, usually about a paragraph (200-400 words) long. A
well-written abstract can let readers get the essence of your paper, prepare readers to follow the detailed information, analyses,
and arguments in your full paper, and help readers remember the key points.
Keywords: Keyword1, Keyword2 … Keyword8
1. Introduction
This template, created in MS Word 2000/2007/2010 and
saved as ―Word 97-2000 & 6.0/95 – RTF‖ for the PC,
provides authors with most of the formatting specifications
needed for preparing electronic versions of their papers. All
standard paper components have been specified for three
reasons: (1) ease of use when formatting individual papers,
(2) automatic compliance to electronic requirements that
facilitate the concurrent or later production of electronic
products, and (3) conformity of style throughout a journal
publication. Margins, column widths, line spacing, and type
styles are built-in; examples of the type styles are provided
throughout this document. Some components, such as
multi-leveled equations, graphics, and tables are not
prescribed, although the various table text styles are
provided. The formatter will need to create these
components, incorporating the applicable criteria that
follow.
2. Custom Title
(SciencePG-Level1-Multiple-line)
2.1. SciencePG-Level2
First, confirm that you have the correct template for your
paper size. This template has been tailored for output on the
A4 paper size.
Comment [A1]:
1) The article should be written in
English.
2) An article should be between 6 and
25 pages, and exceed 2000 words.
3) The article should be composed of
title, author(s), affiliation(s), email(s),
abstract, keywords, introduction, main
body, conclusion, and references.
Comment [A2]:
1) The title should be at least 7 words
but no more than 25 words.
2) The title should be a declarative
phrase without punctuation at the end
of it.
Comment [A3]:
1) Please clearly indicate the full
name of each author.
2) There should be no professional
title/ranks before the author's name.
Comment [A4]:
The affiliation of the author should
only include Department/Faculty,
University/Institute/Organization, City,
Country or ―Company, City, Country‖.
Comment [A5]:
Please write the corresponding
author’s name after each email
address.
Comment [A6]:
2.2. SciencePG-Level2 The number of words in the ―Abstract‖
should be at least 200 words but no
The template is used to format your paper and style the text. more than 400 words. The contents of
All margins, column widths, line spaces, and text fonts are ―Abstract‖ should be structured in one
prescribed; please do not alter them. You may note paragraph without formulas, pictures
peculiarities. For example, the head margin in this template and in-text citations.
measures proportionately more than is customary. This Comment [A7]:
measurement and others are deliberate, using specifications The keywords should include at least
that anticipate your paper as one part of the entire publication, 3 words/phrases but no more than 8.
and not as an independent document. Please do not revise any Comment [A8]:
of the current designations. 1) The headings or subheadings
should be numbered in order as the
2.2.1. SciencePG-Level3 given style.
Before you begin to format your paper, first write and save 2) Each headings or subheadings
the content as a separate text file. Keep your text and graphic should not exceed 3 lines.
files separate until after the text has been formatted and styled. 3) There should be at least 2
Do not use hard tabs, and limit use of hard returns to only one subheadings but no more than 10
subheadings under one heading. For
return at the end of a paragraph. Do not add any kind of example, there should be at least two
pagination anywhere in the paper. Do not number text subheadings (such as 2.2.1 and 2.2.2)
heads-the template will do that for you. under the heading 2.2.
2.2.2. Abbreviations (SciencePG-Level3)
Define abbreviations and acronyms the first time they are
used in the text, even after they have been defined in the
abstract. Abbreviations such as IEEE, SI, MKS, CGS, sc, dc,
and rms do not have to be defined. Do not use abbreviations
in the title or heads unless they are unavoidable.
2 Author Name et al.: Paper title

2.2.3. Equations (SciencePG-Level3) this level of image detail, all three basic varieties of configural
The equations are an exception to the prescribed information (hange of spatial quantization between 11
specifications of this template. You will need to determine pixels/face and 6 pixels/face levels altogether indicate that this
whether or not your equation should be typed using either the ERP- component is especially sensitive to the first-order
Times New Roman or the Symbol font (please no other font). configural cues. Some other works have supported both of
To create multileveled equations, it may be necessary to treat these ideas.
the equation as a graphic and insert it into the text after your
paper is styled.
Equation numbers, within parentheses, are to position flush
right, as in (1), using a right tab stop. To make your equations
more compact, you may use the solidus ( / ), the exp function,
or appropriate exponents. Italicize Roman symbols for
quantities and variables, but not Greek symbols. Use a long
dash rather than a hyphen for a minus sign. Punctuate
equations with commas or periods when they are part of a
sentence, as in
(a) (b) (c)
X+Y=Z (1) Figure 2. There are three figures illustrated here.

X1-Y2=R* (2) 3.2. Table (SciencePG-Level2) Comment [Admin9]:

Note that the equation is centered using a center tab stop. Be 1) The formula should be editable
Table is as follows: Use words rather than symbols or with no image format.
sure that the symbols in your equation have been defined abbreviations when writing Figure axis labels to avoid 2) The superscript and subscript should
before or immediately following the equation. Use ―(1)‖, not confusing the reader. As an example, write the quantity be clearly shown in a formula.
―Eq. (1)‖ or ―equation (1)‖, except at the beginning of a ―Magnetization‖, or ―Magnetization, M‖, not just ―M‖. 3) The formula should be numbered in
sentence: ―Equation (1) is . . .‖ order with Arabic numerals in
Table 1. Table information parentheses after each formula.
3. SciencePG-Level1 Column1 Column2 Comment [A11]:
Row1* Row1 1) Table captions should be clear and
3.1. Figure (SciencePG-Level2) Row2 Row2 be put above the table.
Row3 Row3 2) All tables should be editable with no
Figure is as follows: Place figures and tables at the top and Row4 Row4 image format.
bottom of columns. Avoid placing them in the middle of Row5 Row5 3) Tables should be numbered with
columns. Large figures and tables may span across both Row6 Row6 Arabic numerals in the unified style,
Row7 Row7 such as Table 1, Table 2, Table 3...
columns. Figure captions should be below the figures; table
4) The corresponding meaning of the
heads should appear above the tables. Insert figures and tables *
The example for this table. symbol in the table should be given
after they are cited in the text. Use the ―Figure 1‖, even at the below the table.
beginning of a sentence. 3.3. In-text citations (SciencePG-Level2)

The template will number citations consecutively within

brackets [1]. The sentence punctuation follows the bracket [2]. Comment [A12]:
Refer simply to the reference number, as in [3]—do not use 1) The in-text citations should be
―Ref. [3]‖ or ―reference [3]‖ except at the beginning of a written in the unified form, such as [1],
sentence: ―Reference [3] was the first . . .‖ [2], [3] and so on. For example, [1]
Number footnotes separately in superscripts. Place the should be written in a normal text form
actual footnote at the bottom of the column in which it was instead of in superscript ―[1]‖.
cited. Do not put footnotes in the reference list. Use letters for 2) If there are two or more sources
cited in the same sentence or
table footnotes. paragraph, please enclose all the
Unless there are six authors or more give all authors' names; citations in one bracket, such as [2, 3],
do not use ―et al.‖. Papers that have not been published, even if [6-8] and [4, 9-12].
they have been submitted for publication, should be cited as
―unpublished‖ [4-8]. Papers that have been accepted for Comment [Admin10]:
publication should be cited as ―in press‖ [9-12]. Capitalize 1) Figures should be numbered in
only the first word in a paper title, except for proper nouns and order with clear captions.
Figure 1. The caption of the figure.
element symbols. 2) The captions should be editable and
For papers published in translation journals, please give the be written below the figures.
English citation first, followed by the original 3) Figures should be numbered just
If the square-shaped pixel size in our images was 8 × 8 with Arabic numerals in the unified
screen-pixels, this amounted to about 21 pixels per face foreign-language citation [13-15].
style, such as Figure 1, Figure 2,
quantization (an equivalent of about 10.5 cycles/face). With Figure 3...
 The issue name 2022; X(X): XX-XX
4. Conclusion
After the text edit has been completed, the paper is ready for
the template. Duplicate the template file by using the Save As
command, and use the naming convention prescribed by your
conference for the name of your paper. In this newly created
file, highlight all of the contents and import your prepared text
file. You are now ready to style your paper; use the scroll
down window on the left of the MS Word Formatting toolbar.
Acknowledgements
You as the author are free to decide whether to include
acknowledgments or not. Usually, the acknowledgments
section includes the names of people who in some way
contributed to the work, but do not fit the criteria to be listed
as the authors. This section of your manuscript can also
include information about funding sources.
References
[1] Alimehmeti, I. (2021). Efficacy and Safety of AZD1222,
BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2.
Albanian Journal Of Trauma And Emergency Surgery, 5(1),
791-796. doi: 10.32391/ajtes.v5i1.178
[2] Bos, F., & Ruijs, A. (2021). Quantifying the Non-Use Value of
Biodiversity in Cost–Benefit Analysis: The Dutch
Biodiversity Points. Journal Of Benefit-Cost Analysis, 12(2),
287-312. doi: 10.1017/bca.2020.27
[3] Bryant, A., Lawrie, T., & Fordham, E. (2021). Ivermectin for
Prevention and Treatment of COVID-19 Infection: A
Systematic Review, Meta-analysis, and Trial Sequential
Analysis to Inform Clinical Guidelines. American Journal of
Therapeutics, 28, e434–e460, July 2021. American Journal Of
Therapeutics, 28(5), e573-e576. doi:
10.1097/mjt.0000000000001442
[4] CZucman, N., Uhel, F., Descamps, D., Roux, D., & Ricard, J.
(2021). Severe Reinfection With South African Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant
501Y.V2. Clinical Infectious Diseases. doi:
10.1093/cid/ciab129
[5] Drupp, M., & Hänsel, M. (2021). Relative Prices and Climate
Policy: How the Scarcity of Nonmarket Goods Drives Policy
Evaluation. American Economic Journal: Economic Policy,
13(1), 168-201. doi: 10.1257/pol.20180760
3
[6] Hariyanto, T., Halim, D., Rosalind, J., Gunawan, C., &
Kurniawan, A. (2021). Ivermectin and outcomes from
Covid ‐ 19 pneumonia: A systematic review and meta ‐
analysis of randomized clinical trial studies. Reviews In
Medical Virology. doi: 10.1002/rmv.2265
[7] Hill, A., Garratt, A., Levi, J., Falconer, J., Ellis, L., & McCann,
K. et al. (2021). Meta-analysis of randomized trials of
ivermectin to treat SARS-CoV-2 infection. Open Forum
Infectious Diseases. doi: 10.1093/ofid/ofab358
[8] Klompas, M. (2021). Understanding Breakthrough Infections
Following mRNA SARS-CoV-2 Vaccination. JAMA. doi:
10.1001/jama.2021.19063
[9] Kory, P., Meduri, G., Varon, J., Iglesias, J., & Marik, P. (2021).
Review of the Emerging Evidence Demonstrating the Efficacy
of Ivermectin in the Prophylaxis and Treatment of COVID-19.
American Journal Of Therapeutics, 28(3), e299-e318. doi:
10.1097/mjt.0000000000001377
[10] Kow, C., Merchant, H., Mustafa, Z., & Hasan, S. (2021). The
association between the use of ivermectin and mortality in
patients with COVID-19: a meta-analysis. Pharmacological
Reports, 73(5), 1473-1479. doi: 10.1007/s43440-021-00245-z
Comment [A13]:
[11] Marciniak, S., Farrell, J., Rostron, A., Smith, I., Openshaw, P., 1) This part is to list all the literature
& Baillie, J. et al. (2021). COVID-19 pneumothorax in the that has been cited in the article,
UK: a prospective observational study using the ISARIC including journal articles, books, web
WHO clinical characterisation protocol. European Respiratory pages, etc.
Journal, 58(3), 2100929. doi: 10.1183/13993003.00929-2021 Taking the journal article as an
example, the reference should include
[12] Mukarram, M. (2021). Ivermectin Use Associated with the author's name, the published year,
Reduced Duration of Covid-19 Febrile Illness in a Community
the paper title, the journal name, the
Setting. International Journal Of Clinical Studies And Medical
volume and the issue, the pages.
Case Reports, 13(4). doi: 10.46998/ijcmcr.2021.13.000320
2) Please list at least 15 references.
[13] Okumuş, N., Demirtürk, N., Çetinkaya, R., Güner, R., Avcı, İ., 3) The reference should be numbered
& Orhan, S. et al. (2021). Evaluation of the effectiveness and in the unified form, such as [1], [2],
safety of adding ivermectin to treatment in severe COVID-19 [3]...
patients. BMC Infectious Diseases, 21(1). doi:
10.1186/s12879-021-06104-9
[14] Yeh, H. (2021). The Potential Declining Efficacy of the
ChAdOx1 nCoV-19 Vaccine (AZD1222) on Inoculators With
Nonsteroidal Anti-inflammatory Drug (NSAID) Intake.
Clinical Infectious Diseases. doi: 10.1093/cid/ciab516
[15] Zaidi, A., & Dehgani-Mobaraki, P. (2021). RETRACTED
ARTICLE: The mechanisms of action of Ivermectin against
SARS-CoV-2: An evidence-based clinical review article. The
Journal Of Antibiotics. doi: 10.1038/s41429-021-00430-5